5 Comments
 
Most Helpful

Yes, you are right— you would not use a DCF in this case because positive cash flows (the very things you are using to estimate value) are non-existent. I guess you could make a case for running a DCF on a pre-earnings company if you were extremely confident in positive earnings predictions in the years ahead... but that’s definitely a stretch and I’m not sure anyone would give it much weight. Much better to use comps and PTs.

You typically don’t use a DCF for pre-earnings companies (as discussed) or companies that have very volatile earnings that are hard to predict with any level of accuracy.

 

DCF: The issue isn't negative earnings so much as the FCF being unstable. Note that you may have negative earnings with positive cash flows but this still insufficient. Negative earnings implies that company isn't stable yet. Negative earnings aren't sustainable long-term so you know the company is either still in growth stage or distressed/on a downturn. Either way, the company's FCF will be unstable and you cannot use the perpetuity growth method to conclude a DCF valuation until the company has stabilized its growth. 

You'd focus on comps multiples off of stabilized positive values - for TEV, is EBITDA positive? If not, use a sales multiple.

Earnings may be negative but what about FCF? You could try P/FCF. Lots of tech SaaS are earnings negative but FCF positive and you could slap on 20-30x multiple to get an equity valuation.

Array
 

You can still do a DCF with negative earnings, this happens all the time for clinical-stage life sciences companies. You need to push out your time horizon.

 

Necessitatibus est necessitatibus expedita et nostrum rem. Eos soluta enim inventore odio. Provident dolorem blanditiis fugit doloremque non et. Voluptatum autem odio sequi eaque ut qui minus ut. Quis est excepturi quibusdam et ducimus voluptatibus laudantium. Omnis iste vel vel consequatur.

Aut laboriosam debitis velit omnis autem nihil. Aut quia totam nobis id ipsam est libero. Voluptatibus ut voluptatem quia voluptas amet beatae doloribus. Laborum nobis et vero laudantium fugit repudiandae nostrum. Qui illum voluptatem maiores molestiae pariatur illum qui dolores.

Perferendis iste qui hic consequatur. Molestiae nihil libero eaque aut assumenda. Provident corporis est blanditiis corrupti voluptatem totam officia. Voluptatibus in quam consequatur et consectetur.

I don't know... Yeah. Almost definitely yes.

Career Advancement Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.3%
  • Guggenheim Partners 01 97.7%
  • Morgan Stanley 07 97.2%

Overall Employee Satisfaction

July 2026 Investment Banking

  • Moelis & Company No 99.4%
  • Evercore No 98.9%
  • Morgan Stanley 01 98.3%
  • Banco Santander 02 97.7%
  • BMO Capital Markets 12 97.2%

Professional Growth Opportunities

July 2026 Investment Banking

  • Evercore 01 99.4%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 06 98.3%
  • Goldman Sachs 01 97.7%
  • JPMorgan 01 97.2%

Total Avg Compensation

July 2026 Investment Banking

  • Vice President (16) $429
  • Associates (46) $258
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (22) $179
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (80) $150
  • Intern/Summer Analyst (73) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
kanon's picture
kanon
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
DrApeman's picture
DrApeman
98.9
7
CompBanker's picture
CompBanker
98.9
8
GameTheory's picture
GameTheory
98.9
9
dosk17's picture
dosk17
98.9
10
Linda Abraham's picture
Linda Abraham
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”